The effect of dicyclohexylamine and fumagillin on Nosema ceranae-infected honey bee (Apis mellifera) mortality in cage trial assays by van den Heever, Johan P. et al.
HAL Id: hal-01532345
https://hal.archives-ouvertes.fr/hal-01532345
Submitted on 2 Jun 2017
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
The effect of dicyclohexylamine and fumagillin on
Nosema ceranae-infected honey bee (Apis mellifera)
mortality in cage trial assays
Johan P. van den Heever, Thomas S. Thompson, Simon J. G. Otto, Jonathan
M. Curtis, Abdullah Ibrahim, Stephen F. Pernal
To cite this version:
Johan P. van den Heever, Thomas S. Thompson, Simon J. G. Otto, Jonathan M. Curtis, Abdullah
Ibrahim, et al.. The effect of dicyclohexylamine and fumagillin on Nosema ceranae-infected honey bee
(Apis mellifera) mortality in cage trial assays. Apidologie, Springer Verlag, 2016, 47 (5), pp.663-670.
￿10.1007/s13592-015-0411-9￿. ￿hal-01532345￿
The effect of dicyclohexylamine and fumagillin on Nosema
ceranae -infected honey bee (Apis mellifera ) mortality
in cage trial assays
Johan P. VAN DEN HEEVER1, Thomas S. THOMPSON1, Simon J. G. OTTO1,2,
Jonathan M. CURTIS3, Abdullah IBRAHIM4, Stephen F. PERNAL4
1Alberta Agriculture and Forestry, Food Safety Division, Agri-Food Laboratories Branch, 6909-116 Street, Edmonton,
Alberta T6H 4P2, Canada
2School of Public Health, University of Alberta, Edmonton, Alberta T6G 1C9, Canada
3Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta T6G 2P5, Canada
4Agriculture and Agri-Food Canada, Beaverlodge Research Farm, P.O. Box 29, Beaverlodge, Alberta T0H 0C0, Canada
Received 24 June 2015 – Revised 1 October 2015 – Accepted 5 November 2015
Abstract – Both commercially available fumagillin-based treatments for honey bees (Apis mellifera ), Fumagilin-
B® as well as Fumidil-B®, contain the reportedly genotoxic and tumorigenic compound dicyclohexylamine (DCH)
as the counter ion in the fumagillin-DCH salt. The effect of DCH, purified fumagillin (containing no DCH), and the
commercial formulation Fumagilin-B® (containing both fumagillin as well as DCH) on the mortality of caged
Nosema ceranae -infected honey bees was investigated. A statistically significant risk of bee mortality associated
with oral exposure to DCH was observed. DCH is also known to be significantly more stable than fumagillin in
honey under a variety of temperature conditions, both in the presence and absence of light. The presence of DCH in
the hive is therefore a potential concern for bee health and also for food safety.
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1. INTRODUCTION
Fumagillin (Figure 1) was discovered nearly
70 years ago (Hanson and Eble 1949, Eble and
Hanson 1951). and its efficacy against Nosema
apis infections (Zander 1909) plaguing the honey
bee (Apis mellifera L.) was soon realized
(Katznelson and Jamieson 1952, Bailey 1953).
The more recently reported Nosema ceranae
(Fries et al. 1996) infection of the western honey
bee forms part of the pathogen complex collec-
tively referred to as “nosema disease.”N. apis and
N. ceranae are distinctly different single-cellular
microsporidian fungal parasites which have been
associated with high levels of bee loss worldwide,
with both N. apis and N. ceranae being implicat-
ed as part of the pathogen complex associated
with the colony collapse disorder (CCD) phenom-
enon (Cox-Foster et al. 2007; Martín-Hernández
et a l . 2007; Higes e t a l . 2008, 2009;
vanEngelsdorp et al . 2009). Currently,
Fumagilin-B® is the only registered antibiotic
available to treat both N. apis and N. ceranae
infections of honey bees in North America, al-
though it is reportedly not as effective against
N. ceranae (Williams et al. 2008, 2011).
Fumagillin, sold as Fumidil-B® in Europe, is re-
portedly only allowed for use under special cir-
cumstances in parts of Europe, including Spain
and some Balkan countries (Higes et al. 2011,
Stevanovic et al. 2013). and is not available for
general use.
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A review paper (van den Heever et al. 2014)
recently pointed out that the commercial formula-
tions of fumagillin contain fumagillin as a salt,
with dicyclohexylamine (DCH) being the counter
ion of fumagillin in this salt (Figure 1). It is
therefore important to realize that both fumagillin
and DCH are present in a 1:1 stoichiometric ratio
when applying either of the commercial formula-
tions. DCH is reportedly genotoxic (Stanimirović
et al. 2010) as well as tumorigenic (Sigma-Aldrich
MSDS 185841 v. 5.0 Rev. 07/24/2012), and ap-
plication of either Fumagilin-B® or Fumidil-B®
implies that the same amount of the biologically
active DCH is also being applied at the same time.
For a more comprehensive discussion on the tox-
icity of fumagillin and DCH, the reader is referred
to a recent review (van den Heever et al. 2014).
During our previous research using N. ceranae -
infected caged bees to evaluate alternative chemo-
therapies for use against this parasite, we observed
bee mortalities in the positive control cages being
treated with Fumagilin-B® of up to 71 % (van den
heever et al. 2015c). In these trials, the treatment
dose was 40 μM in 60 % sucrose syrup solution.
The observed mortality rates also increased with
an increase in Fumagilin-B® concentration. It was
therefore suspected that the elevated bee mortality
associated with Fumagilin-B® usage could be as-
cribed to the presence of either DCH or fumagillin
in the commercial products. The present study
was thus undertaken to evaluate changes in adult
bee survival and N. ceranae treatment efficacy
associated with feeding caged bees with DCH
only (no fumagillin), pure fumagillin (no DCH),
as well as with the commercially available
Fumagilin-B®, consisting of both fumagillin as
well as DCH.
2. MATERIALS AND METHODS
2.1. Reagents and materials
Pure fumagillin isolated from Aspergillus
fumigatus containing no DCH (Cat. # F6771),
and dicyclohexylamine nitrite (Cat. # 317837)
was obtained from Sigma-Aldrich (St. Louis,
MO, USA). The commercial formulation of
fumagillin, Fumagilin-B®, containing fumagillin
as the DCH salt, was obtained from Medivet
Pharmaceuticals Ltd (High River, AB, Canada;
DIN 02231180).
2.2. Cage assays
Cage assays were conducted during 2013.
Adult honey bees (A. mellifera ) for the assays
were obtained from several colonies at
Agriculture and Agri-Food Canada’s Research
Farm, in Beaverlodge, Alberta, Canada (55° 18′
N; 119° 17′ W) by collecting frames of sealed
brood with newly eclosing bees. These colonies
were repeatedly tested in order to establish wheth-
er they were free from both N. apis and
N. ceranae infections, using both light micro-
scopic and molecular methods (described below).
Frames were kept overnight in an incubator
(Percival Model 136NLC9, Percival Scientific
Inc., Perry, IA, USA) maintained at hive temper-
ature (33±0.5 °C) and relative humidity (70±5%).
Adult workers were pooled and mixed from
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Figure 1. The commercial Fumagilin-B® (or Fumidil-B®) containing fumagillin (a ) as the dicyclohexylamine (b ) salt.
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all frames, with 100 being added to wooden
screened cages (8.0×9.5×12.0 cm ID) for the
cage assay. Bees were then fed 4 mL of a 60 %
(w /v ) of aqueous sucrose syrup for 24 h, using
gravity feeders made from disposable centrifuge
tubes (Cat. #93000-020, VWR International,
Radnor, PA, USA).
After the initial 24-h feeding period with the
60 % sugar syrup, each cage was mass inoculated
with 5 mL of a 60 % syrup solution containing 1×
107 freshly harvested N. ceranae spores. Spores
were prepared from previously identified colonies
of honey bees with established high levels of
N. ceranae infection. Workers from these colo-
nies were euthanized on dry ice, followed by
removal of their abdomens, which were then
suspended in ultrapure water (1 mL per bee).
After maceration, the crude suspension was fil-
tered through a sieve (∼0.8 mm) in order to re-
move large body parts, and the resulting crude
macerate was then counted, according to methods
below, in order to prepare a solution with the
correct inoculation dose. Some of the crude mac-
erate was frozen for use in subsequent Nosema
spp. identification. After consumption of the inoc-
ulum for 48 h, cages of bees were fed ad libitum
for 17 days with the three test compounds, or
groups of compounds, consisting of fumagillin
only, DCH only, as well as the commercially
available Fumagilin-B® (fumagillin and DCH),
all at a single concentration of 40 μM in 60 %
sucrose syrup. We were only interested in evalu-
ating the label-dose effects, and therefore, only a
single test concentration was used. A negative
control consisting of a 60 % sucrose solution
was also employed. Six replicate cages of bees
were evaluated for each control, compound, or
mixture of compounds, and the mortality of bees
was recorded each day, up to 17 days post-
inoculation.
2.3. Determination of spore levels
To determine Nosema infection levels in colo-
nies, 60 adult workers were collected from periph-
eral frames of the brood nest. For cage trials, 30
surviving workers were removed from each cage
17 days post-inoculation. Bees were euthanized
and had their abdomens placed into a stomacher
bag containing 70 % ethanol (1 mL per bee). The
abdomens were then macerated for 1 min at me-
dium speed (Seward Stomacher® 80 Biomaster,
Seward Laboratory Systems Inc., Davie, FL,
USA), and 6 μL of the macerate was withdrawn
and loaded onto a Helber Z30000 counting cham-
ber (Hawksley, Lancing, UK), with spores count-
ed according to the generalized methods of
Cantwell (1970) under phase contrast microscopy
at ×400 magnification. Samples of the remaining
crude macerate were portioned into 1.5-mL
microcentrifuge tubes and stored at −20 °C.
2.4. Nosema spp. identification
The crude macerate described in Section 2.3
was vortexed, and then 200–400 μL was centri-
fuged to remove the ethanol from the sample.
DNA extraction was performed using the
DNeasy® Blood & Tissue Kit (Qiagen®,
Valencia, CA, USA). The concentration of the
extracted DNAwas determined spectrophotomet-
rically (NanoDrop 2000C, Thermo Scientific,
West Palm Beach, FL, USA), whereafter 50–
100 ng of this DNA extract was amplified using
polymerase chain reactions (PCR).
A multiplex system that co-amplified the 16S
rRNA gene of N. apis and N. ceranae (Martín-
Hernández et al. 2007) as well as the honey bee
ribosomal protein RpS5 gene (Thompson et al.
2007) was used within the same reaction. A mod-
ified version of the PCR protocol was used, owing
to the fact that early pre-tests indicated that these
modifications increased the sensitivity of simulta-
neous detection of both N. apis and N. ceranae
within any given sample. All PCR reactions were
performed using a Mastercycler® proS
thermocycler (Eppendorf, Mississauga, Canada)
and utilizing the Illustra™ PuReTaq Ready-To-
Go™ PCR beads (GE Healthcare Life Sciences,
Baie d’Urfe, Quebec, Canada). PCR beads were
reconstituted to 25 μL final volume by adding
sterile H2O, 0.5 μL of 20mM forward and reverse
primers (a final concentration of 0.4 mM), and the
DNA (50–100 ng per reaction). To amplify a
218-bp 16S rRNA PCR product specific for
N. ceranae , primers Mitoc-For (5′-CGGCGAC
GATGTGATATGAAAATATTAA-3′) and Mitoc-
Rev (5′-CCCGGTCATTCTCAAACAAAAAA
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CCG-3′) were used, and to amplify a 321-bp 16S
rRNA PCR product specific for N. apis , primers
A p i s - F o r ( 5 ′ - GGGGGCATGTCTTT
GACGTACTATGTA-3′) and Apis-Rev (5′-
GGGGGGCGTTTAAAATGTGAAACAACTA-
TG-3) were used, according to Martín-Hernández
et al. (2007). In addition, the honey bee house-
keeping gene, RpS5, was also amplified within
the same reaction as a reference, which yielded a
PCR product of 115 bp. The primer pairs used
were RpS5-For (5′-AATTATTTGGTCGCTGG
AATTG-3′) and RpS5-Rev (5′-TAACGTCCAG
CAGAATGTGGTA-3′), respectively (Thompson
et al. 2007). The thermocycler program consisted
of an initial DNA denaturation step at 95 °C for
5 min, followed by 35 cycles of 94 °C for 30 s,
61.8 °C for 30 s, and 72 °C for 30 s. A final
extension of 72 °C for 7 min was followed by
holding the reactions at 4 °C until stopped. All
PCR products were visualized on a 2 % agarose
gel and stained with SYBR® Safe DNA gel stain
(Life Technologies, Carlsbad, CA, USA).
2.5. Statistical analysis
Data was analyzed using semi-parametric, Cox
proportional hazards models with a complimenta-
ry log-log link for survival data (Corrente et al.
2003, Dohoo et al. 2009). The bee survival for
indicator variables for each treatment group was
considered against negative controls using likeli-
hood ratio test (LRT; P≤0.05). To test for propor-
tional hazards across treatment groups, an
interaction between treatment group and survival
time was considered. A LRT P≤0.05 indicated
non-proportional hazards, which was solved by
including the interaction in the model. Linear
regression was used to assess the effects of these
treatment methods on the natural log of spore
counts to normalize the data (zero spore counts
were changed to one to allow for the log value to
be zero). The effect of an indicator variable treat-
ment group was tested using the extra sum of
squares F-test (Dohoo et al. 2009). The model
was assessed for fitness by evaluating the normal-
ity and homoscedasticity of the standardized re-
siduals. All analysis was conducted in Excel 2010
(Microsoft Corporation, Redmond, WA, USA)
and STATA Intercooled 13.1 (StataCorp LP,
College Station, TX, USA).
3. RESULTS
The Cox proportional hazards model found that
the treatment group and an interaction between
the treatment group and survival time were signif-
icant (LRT P<0.01 for both). This indicated that
the hazards for each treatment group varied over
time.
The predicted hazards by treatment group are
shown in Figure 2. Specific comparisons between
two treatments at distinct time points (hazard ra-
tios) are shown in Table I. For the first 10 days of
the trial, there were no obvious differences in the
hazards (probability of death) for any treatment
group. Starting on day 11, the commercial
Figure 2. The predicted hazards from the complimentary log-log, Cox proportional hazards survival model for the
cage trial to assess toxicity of dicyclohexylamine (DCH), fed ad libitum at a concentration of 40 μM in 60 % sugar
solution, to bees infected with N. ceranae over 17 days of treatment.
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Fumagilin-B® (fumagillin with DCH) was ob-
served to have significantly higher bee mortality
than any other group. By day 13, both Fumagilin-
B® and DCH alone had significantly higher mor-
tality than either the control or purified fumagillin,
but not from one another. Commercial Fumagilin-
B® and purified DCH consistently had higher bee
mortality than purified fumagillin after day 11.
There were no significant differences in mortality
between the purified fumagillin and the control
group.
The results of the linear regression model for
spore counts in the comparative cage trials to
assess the effects of DCH are shown in Table II.
The treatment was significantly associated with
altered spore counts (P≤0.01). The commercial
Fumagilin-B® reduced spore counts to zero in all
replicates, which was a significant reduction (in
the order of millions), compared to all other
groups, including the purified fumagillin group
(P≤0.01 for all). Purified fumagillin (no DCH)
significantly reduced the spore count compared
to the control and pure DCH groups (P≤0.01 for
both); however, the spore reduction was in the
order of 20 times less for both, which has ques-
tionable clinical significance. Residuals from the
model were normally distributed and homosce-
dastic (data not shown).
4. DISCUSSION
It is important to remember that Fumagilin-B®
is commercially sold as the dicyclohexylamine
(DCH) salt, containing both fumagillin and DCH
in a 1:1 stoichiometric ratio (Figure 1, compounds
a and b). Using Fumagilin-B® or Fumidil-B®
therefore introduces not only one, but two poten-
tially biologically active compounds to the bee
hive (van den Heever et al. 2014). We observed
that the risk of bee mortality of N. ceranae -infect-
ed caged bees treated with DCH alone was not
statistically different compared to the commercial
Fumagilin-B® for most of the study period, with
the exception of days 11 and 17 (Table II). Bees
treated with DCH or commercial Fumagilin-B®
had significantly higher risk of mortality com-
pared with controls or those treated with purified
fumagillin for most days after day 11, with a few
exceptions (Table II). This indicates that the
Table I. Results of the complimentary log-log, Cox
proportional hazards survival model for the cage trial
to assess toxicity of dicyclohexylamine (DCH), fed ad
libitum at a concentration of 40 μM in 60 % sucrose
solution, to bees infected with N. ceranae over 17 days
of treatment
Treatment HR P value 95 % CI
DCH only vs. negative control
Day 11 0.97 0.96 0.31–3.02
Day 13 3.66 0.01 1.48–9.02
Day 15 2.20 0.01 1.21–4.00
Day 16 1.36 0.24 0.81–2.28
Day 17 4.34 <0.01 2.78–6.77
Fumagilin-B® vs. negative control
Day 11 3.44 0.01 1.38–8.57
Day 13 3.06 0.02 1.21–7.76
Day 15 1.77 0.07 0.95–3.32
Day 16 1.34 0.27 0.79–2.27
Day 17 1.94 0.01 1.18–3.20
Fumagillin only vs. negative control
Day 11 1.23 0.71 0.41–3.67
Day 13 0.35 0.20 0.07–1.74
Day 15 0.66 0.31 0.30–1.46
Day 16 0.36 0.01 0.17–0.76
Day 17 0.60 0.11 0.31–1.13
DCH only vs. fumagillin only
Day 11 0.79 0.67 0.27–2.35
Day 13 10.40 <0.01 2.45–44.22
Day 15 3.33 <0.01 1.64–6.76
Day 16 3.82 <0.01 1.82–8.00
Day 17 7.27 <0.01 4.20–12.57
Fumagilin-B® vs. fumagillin only
Day 11 2.79 0.02 1.18–6.60
Day 13 8.70 <0.01 2.01–37.66
Day 15 2.68 0.01 1.29–5.58
Day 16 3.77 <0.01 1.79–7.93
Day 17 3.25 <0.01 1.80–5.89
Fumagilin-B® vs. DCH only
Day 11 3.53 0.01 1.42–8.79
Day 13 0.84 0.58 0.44–1.58
Day 15 0.80 0.41 0.48–1.35
Day 16 0.99 0.96 0.60–1.62
lDay 17 0.45 <0.01 0.31–0.65
HR hazard ratio, CI confidence interval
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observed bee mortality associated with the use of
the commercial Fumagilin-B® could likely be as-
cribed to the presence of DCH in the formulation.
DCH has also been shown to be significantly
more stable in honey under a variety of conditions
(van den Heever et al. 2015a). When incurred
honey samples were analyzed, these experimental
observations were confirmed when it was found
that DCH was present at significant concentra-
tions in honey, even when no fumagillin is detect-
able (van den Heever et al. 2015a). In the present
study, the beneficial properties of purified
fumagillin were however observed to be almost
20 times lower than that of the commercial
Fumagilin-B®. This is presumably due to the fact
that the purified fumagillin is not chemically
stabilized as a salt, and is therefore presumably
prone to decomposition during handling and
application.
Other hive products such as wax need to be
examined for DCH contamination, since
accumulation of DCH in the comb wax could
negatively impact the development of young
bee larvae, which are in close proximity to the
wax comb at a stage of their lifecycle that make
them more susceptible to the influence of
substances like DCH. The environmental
prevalence of DCH also needs to be established
in order to ascertain if this route of contamination
is indeed of concern not only for beekeeping, but
also for human health (van den Heever et al.
2014).
Another aspect of DCH in apiculture that re-
quires further study are the potential synergistic
effects resulting from the combination of DCH
and other known chemical contaminants in the
hive. Previous research has shown that combined
exposure to Fumagilin-B® and to tau -fluvalinate
leads to an increase in tau -fluvalinate toxicity to
honey bees, resulting in higher bee mortality
(Johnson et al. 2013). Tau -fluvalinate was report-
edly the most abundant pyrethroid found in North
American apiaries in wax (98.1 % detection at a
median concentration of 3595 ng g−1), pollen
(88.3 % detection at a median concentration of
5860 ng g−1), and bees (83.6 % detection at a
median concentration of 3595 ng g−1), according
to a 2010 study (Mullin et al. 2010). The concen-
tration of Fumagilin-B® used for the synergism
study (designed to evaluate sub therapeutic con-
centration effects) was however only 0.78 μM
(Johnson et al. 2013). which is 50 times less than
the manufacturer’s prescribed therapeutic dosage
of 40 μM for Fumagilin-B®, containing both
fumagillin and DCH in equal amounts. This study
indicated that a significant increase in toxic syn-
ergism with tau -fluvalinate can therefore be ex-
pected at the therapeutic concentration of Fumidil-
B® (or Fumagilin-B®). It would be interesting to
establish whether it is fumagillin or whether it is
Table II. Results of linear regression model for the cage trial to assess the effects of various treatment preparations
with or without dicyclohexylamine (DCH), fed ad libitum at a concentration of 40 μM in 60 % sugar solution, on
spore counts in bees infected with N. ceranae over 17 days of treatment
Compound Median spores
(106/bee)
SDa (106) Coefficient
(spores/bee)
P value 95 % CIb
Negative control 12.0 3.72 Referent –
DCH only 13.0 4.51 1 0.47 −1 to 2
Fumagilin-B® 0 0 −12.38e+6 <0.01 (−19.64 to −7.91) e+6
Fumagillin only 0.75 0.29 −21 <0.01 −33 to −13
Fumagilin-B® vs. fumagillin only – – −0.59e+6 <0.01 (−0.93 to −0.37) e+6
Fumagilin-B® vs. DCH only – – −14.53e+6 <0.01 (−23.05 to −9.16) e+6
Fumagillin only vs. DCH only – – −25 <0.01 −39 to −16
e exponent (−12.38e+6 =−12,380,000)
a Standard deviation
b Confidence interval
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DCH that was responsible for the observed syn-
ergistic effect, since the commercially available
Fumidil-B® was used in the synergism study
(Johnson et al. 2013). Pyrethroids, including
tau -fluvalinate, are reportedly also very stable in
wax, where they can accumulate, with estimated
half-lives of approximately 5 years (Bogdanov
2004). In previous reports, the half-life of DCH
was observed as being approximately 1–3 years in
honey under various simulated conditions exam-
ined (van den Heever et al. 2015a). DCH can
therefore be expected to accumulate in wax, and
also to exhibit a long half-life in this matrix, but
this remains to be confirmed. The continuous
usage of Fumagilin-B® (and Fumidil-B®) since
almost 1950 (van den Heever et al. 2014). com-
bined with its suspected prevalence and stability
in wax, makes it highly likely that DCH will be
present at elevated concentrations in this matrix.
In light of this, and combined with our observa-
tions regarding the increased risk to bee mortality
resulting from DCH exposure, it is important that
the current analytical methodology be expanded
to quantify DCH and fumagillin not only in honey,
but also in other hive matrices such as in wax and
perhaps in pollen. The synergistic effects of both
DCH and fumagillin not only on tau -fluvalinate,
but also on other frequently found chemical
residues in the hive, warrants further research.
5. CONCLUSIONS
Evaluation of the toxicity of the DCH, which is
present in a 1:1 stoichiometric ratio to fumagillin
in the commercial formulations of fumagillin,
showed that DCH increases bee mortality. The
genotoxic and mutagenic properties of DCH,
combined with its lipophilicity, could lead to its
accumulation in comb wax, where it could poten-
tially impact the development of the developing
bee larvae and pupa. DCH is also a contaminant of
concern in hive products, with regard to food
safety and human health. The frequent detection
of DCH residues in honey by LC-MS/MS, even in
the absence of detectable fumagillin residues, has
been previously reported (van den Heever et al.
2015b). The risk to the consumer associated with
DCH residues in honey should be evaluated. DCH
was also reported to be significantly more stable
than fumagillin in honey (van den Heever et al.
2015a). A different formulation of fumagillin
using a less toxic counter ion to form the salt
would be beneficial. An example of such a coun-
ter ion could be meglumine, which is acceptable
for human pharmaceutical use as a non-toxic
counter ion that is used to crystallize carboxylic
acid pharmaceuticals destined for human use. The
use of a suitable non-toxic counter ion would
eliminate DCH from the commercial fumagillin
formulation and would clearly benefit bee health,
as well as improve the quality of honey destined
for human consumption.
L’effet de la dicyclohexylamine et de la fumagilline sur
la mortalité d’abeilles (Apis mellifera ) infectées par
Nosema ceranae dans des essais en cage
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